Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients

Table 1 The patient demographic data and blood chemistry data

	Benign biliary tract disease	Cholangio-carcinoma	Healthyvolunteers
Sex (Male:Female)	21:20	19:14	6:4
Age (year), (median)	53.68 (22-82)	56.40 (35-85)	49.50 (26-60)
SGOT (IU/dL)	105.32 ± 52.26	112.52 ± 44.54	30.20 ± 12.20
SGPT (IU/dL)	96.04 ± 45.42	73.41 ± 44.30	28.50 ± 9.22
Total Bilirubin (mg/dL)a	3.8 ± 2.21	12.8 ± 5.24	1.05 ± 0.25
Alkaline Phosphatase (U/dL)a	309 ± 67.53	550 ± 24.44	98 ± 10.60

^aP < 0.005.

Table 2 Comparative analysis of serum hTERT mRNA and serum CA19-9 in diagnosis of cholangiocarcinoma

	Serum hTERT (%)	Serum CA19-9 (%)
Sensitivity	84.85	60.6
Specificity	78.05	80.49
Positive predictive value	75.68	71.43
Negative predictive value	86.49	71.74
False Negative	13.51	28.26
False Positive	24.32	28.6

Table 3 Detection of serum hTERT mRNA in relation to tumor staging

Tumor stages	Serum hTERT	mRNA
	positive	negative
Stage I	2	1
Stage II	17	3
Stage III	9	1